The inherited retinal disease (IRD) community is keenly awaiting updates on promising new treatments. In a significant development, Ocugen, Inc., a biotechnology company specializing in gene therapies for blindness, hosted a webcast on Thursday, January 15, 2026, to delve into the one-year treatment data from the initial cohort of patients in its OCU410 Phase 2 ArMaDa clinical trial. This event provided crucial insights into the potential of OCU410, a novel modifier gene therapy candidate for geographic atrophy (GA) secondary to dry age-related macular degeneration (dAMD).

Key Insights from the Webcast

During the webcast, Ocugen, Inc. discussed the one-year treatment data from the first half of patients who completed this milestone in the OCU410 Phase 2 ArMaDa clinical trial. OCU410 is described as a modifier gene therapy candidate for geographic atrophy, a severe form of dry age-related macular degeneration. The presentation featured insights from study investigators, including Arshad M. Khanani from Sierra Eye Associates, Jay Chhablani from the University of Pittsburgh Eye Center, and Lejla Vajzovic from Duke University School of Medicine.

Preliminary 12-month data from the Phase 2 trial, evaluating approximately 50% of patients, showed a 46% reduction in lesion growth when combining medium and high doses compared to control eyes (p=0.015). Specifically, the medium dose group demonstrated a 54% reduction in lesion growth, while the high-dose group showed a 36% reduction, both compared to control. Furthermore, up to 50% of patients achieved more than a 50% reduction in lesion size compared to control.

Importantly, the trial has reported a favorable safety profile. No OCU410-related serious adverse events have been observed in either the Phase 1 or Phase 2 clinical trials to date. There have also been no reported cases of endophthalmitis, retinal detachment, vasculitis, choroidal neovascularization, or optic ischemic neuropathy.

What This Means for Patients and Families

Geographic atrophy affects millions globally, with limited treatment options currently available, particularly outside the U.S. Existing treatments in the U.S. often require frequent injections, which can be burdensome for patients. OCU410 is being developed as a one-time gene therapy, which could significantly reduce the treatment burden if approved. The positive preliminary data, particularly the reduction in lesion growth and the strong safety profile, offer hope for a potentially less invasive and more durable treatment for GA patients.

Ocugen aims to provide a gene-agnostic approach to eye conditions through its modifier gene therapy platform, which targets entire disease complexes rather than single genes. This strategy could address imbalances in multiple gene networks, potentially offering a broader impact on diseases like geographic atrophy.

Looking Ahead

Ocugen plans to report full data from the OCU410 Phase 2 clinical trial later in the quarter and anticipates initiating a Phase 3 trial in 2026. The continued progress of OCU410 through clinical development represents a promising step forward in the search for effective and long-lasting treatments for geographic atrophy.